Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.

Nature reviews. Clinical oncology - 1 Jul 2018

Killock David

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Neoplasms
Share to Carcinoma, Non-Small-Cell Lung
Share to Ipilimumab
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nivolumab

Source

Identifiers

PMID: 29703915
DOI: 10.1038/s41571-018-0034-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Nivolumab-ipilimumab - exploiting the mutation burden of NSCLCs.PMID 29703915Read ↗

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.Semantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.Semantic proximity Read ↗

The emerging development of tumor mutational burden in patients with NSCLC.Semantic proximity Read ↗

Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration.Semantic proximity Read ↗

Nivolumab in non-small-cell lung cancer with EGFR mutation.Semantic proximity Read ↗

[Importance of tumour mutation burden testing].Semantic proximity Read ↗

Mutation load estimation model as a predictor of the response to cancer immunotherapySemantic proximity Read ↗

Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.Semantic proximity Read ↗

Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and OlderSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.